Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | RRM2 | P31350 | 1/20 | 0.39 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.35 |
| ▸ | PLAU | P00749 | 3/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960810 | 0.84 | RRM1 (0.39) | RRM1RRM2RRM2BCISD1GRM4 | |
| SCHEMBL7960813 | 0.84 | RRM1 (0.39) | RRM1RRM2RRM2BCISD1GRM4 | |
| SCHEMBL5263024 | 0.78 | PLAU (0.50) | PLAUMAPTBLMADRA2AADRA2B | |
| SCHEMBL6448847 | 0.78 | PLAU (0.37) | TLR7HSP90AA1PLAUMAPTBLM | |
| SCHEMBL30508919 | 0.78 | PLAU (0.37) | TLR7HSP90AA1PLAUMAPTBLM | |
| SCHEMBL5263016 | 0.78 | PLAU (0.50) | PLAUMAPTBLMADRA2AADRA2B | |
| SCHEMBL4069571 | 0.77 | RRM1 (0.46) | RRM1RRM2RRM2BCISD1GRM4 | |
| SCHEMBL13978251 | 0.75 | GRM4 (0.34) | RRM1RRM2RRM2BCISD1GRM4 | |
| SCHEMBL699068 | 0.75 | MKNK1 (0.49) | GRM4PIM1PIM3TLR7MAPT | |
| SCHEMBL29385675 | 0.75 | MKNK1 (0.49) | GRM4PIM1PIM3TLR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RRM1 2113/4885RRM2 1778/4885RRM2B 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.